The rise of companies from emerging markets in global health governance: opportunities and challenges

摘要: The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers medicines and vaccines and, increasingly, new technologies. In so doing, have facilitated implementation key goal policy: widening access to treatment prevention. Yet, looking closer at political economy underlying their involvement, exposes tension between this policy development production. By declaring pharmaceuticals policy, governments partnerships made themselves dependent on supply them. Moreover, provide prevention level, depend extremely low prices. production is organized around commercial incentives are odds with prices required. increasing mitigates short run. long run, endangers sustainability policies may even undermine some successes already achieved.